1875-9114/asset/olbannerleft.jpg?v=1&s=4adba4607da96723ce49cdd43bedc3fbb9636e99)
1875-9114/asset/olbannerright.jpg?v=1&s=39456f1dfdf599f8cb8138949a73fcd73493c3a5)
CASE REPORT
You have free access to this content
Neurologic Adverse Effects of Ranolazine in an Elderly Patient with Renal Impairment
Article first published online: 10 JAN 2013
DOI: 10.1002/phar.1152
© 2013 Pharmacotherapy Publications, Inc.
Issue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 33, Issue 1, pages e9–e13, January 2013
Additional Information
How to Cite
(Pharmacotherapy 2013;(1):e9–e13)
Publication History
- Issue published online: 10 JAN 2013
- Article first published online: 10 JAN 2013
References
- 1Gilead Sciences, Inc. Ranexa (ranolazine) package insert. Foster City, CA; 2011.
- 2, , , et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375–82.
- 3, , , et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–16.
- 4, , . Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006;92(suppl IV):iv6–14.
- 5. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006;45(5):469–91.
- 6, , , et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297(16):1775–83.
- 7. Current awareness of piperazines: pharmacology and toxicology. Drug Test Anal 2011;3:430–8.
- 8, , . Piperazine compounds as drugs of abuse. Drug Alcohol Depend 2012;122:174–85.
- 9, , . State- and use-dependent block of muscle nav1.4 and neuronal nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol 2008;73:940–8.
- 10, , , , . Ranolazine attenuation of CFA-induced mechanical hyperalgesia. Pain Med 2010;11:119–26.
- 11, , , . Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 2008;28(46):11768–77.
- 12, , . Block of tetrodotoxin-sensitive, Nav1.7 and tetrodotoxin-resistant, NAv1.8, Na+ channels by ranolzaine. Channels 2008;2(6):449–60.
- 13, , , , . Allelic mutations of the sodium channel Scn8a reveal multiple cellular and physiological functions. Genetica 2004;122:37–45.
- 14, , , . Exaggerated emotional behavior in mice heterozygous for the sodium channel Scn8a (Na(v)1.6). Genes Brain Behav 2008;7:629–38.
- 15, . Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 2005;45(7):802–9.
- 16, . Effect of renal impairment on multiple dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005;78(3):288–97.
- 17, , . Acute psychosis associated with oral trimethoprim-sulfamethoxazole therapy. Can J Psychiatry 1993;38:56–8.
- 18, , , . Cotrimoxazole-induced psychosis: a case report and review of literature. Pharmacopsychiatry 2006;39:236–7.
- 19, , . Transient psychosis in an immune-competent patient after oral trimethoprim-sulfamethoxazole administration. Pediatrics 2005;115:e739–41.
- 20, . Iopromide-induced encephalopathy following coronary angioplasty. Perfusion 2011;26(1):67–70.
- 21, , , et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–45.